Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement
The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer. This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017. In this coho...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2020-09, Vol.315, p.86-89 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89 |
|---|---|
| container_issue | |
| container_start_page | 86 |
| container_title | International journal of cardiology |
| container_volume | 315 |
| creator | Biancari, Fausto Dahlbacka, Sebastian Juvonen, Tatu Virtanen, Marko P.O. Maaranen, Pasi Jaakkola, Jussi Laakso, Teemu Niemelä, Matti Tauriainen, Tuomas Vento, Antti Husso, Annastiina Savontaus, Mikko Laine, Mika Mäkikallio, Timo Raivio, Peter Eskola, Markku Rosato, Stefano Anttila, Vesa Airaksinen, Juhani Valtola, Antti |
| description | The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer.
This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017.
In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p |
| doi_str_mv | 10.1016/j.ijcard.2020.03.038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2384210349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527319355469</els_id><sourcerecordid>2384210349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-dd4f0a90c343bbb72fd78ee827e4c8c1b377737e835a21a949529e0a6632f1393</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMoun78A5EevXTNVzfpRRBxVRC8qNcwTaeapW3WJF3w35tl1aMw8F6ed4Z5CDlndM4oW1yt5m5lIbRzTjmdU5FH75EZ00qWTFVyn8wypsqKK3FEjmNcUUplXetDciQ4Z4taVTPytoSND9D0WPgpWT_k7AoLo8VQrCE5HFMsprHF8O7d-F6kAGO0kD4wZQJ8SM4WG-g3WARc92BxyJVTctBBH_HsJ0_I6_Lu5fahfHq-f7y9eSqtpDqVbSs7CjW1QoqmaRTvWqURNVcorbasEUopoVCLCjiDWtYVr5HCYiF4x0QtTsjlbu86-M8JYzKDixb7Hkb0UzRcaMkZFXKLyh1qg48xYGfWwQ0QvgyjZmvUrMzOqNkaNVTk0bl28XNhagZs_0q_CjNwvQMw_7lxGEy02ZrF1gW0ybTe_X_hG_lXie4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2384210349</pqid></control><display><type>article</type><title>Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Biancari, Fausto ; Dahlbacka, Sebastian ; Juvonen, Tatu ; Virtanen, Marko P.O. ; Maaranen, Pasi ; Jaakkola, Jussi ; Laakso, Teemu ; Niemelä, Matti ; Tauriainen, Tuomas ; Vento, Antti ; Husso, Annastiina ; Savontaus, Mikko ; Laine, Mika ; Mäkikallio, Timo ; Raivio, Peter ; Eskola, Markku ; Rosato, Stefano ; Anttila, Vesa ; Airaksinen, Juhani ; Valtola, Antti</creator><creatorcontrib>Biancari, Fausto ; Dahlbacka, Sebastian ; Juvonen, Tatu ; Virtanen, Marko P.O. ; Maaranen, Pasi ; Jaakkola, Jussi ; Laakso, Teemu ; Niemelä, Matti ; Tauriainen, Tuomas ; Vento, Antti ; Husso, Annastiina ; Savontaus, Mikko ; Laine, Mika ; Mäkikallio, Timo ; Raivio, Peter ; Eskola, Markku ; Rosato, Stefano ; Anttila, Vesa ; Airaksinen, Juhani ; Valtola, Antti</creatorcontrib><description>The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer.
This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017.
In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p < 0.0001). Among cancer patients, 18 died of the same disease (at 7 years, mortality 12.5%). Active malignancy was not associated with increased risk of all-cause mortality (adjusted HR 1.100, 95%CI 0.757–1.599). However, patients with blood malignancies had a significantly increased risk of mortality (at 4-year, 53.5% vs. 35.4%, adjusted HR 2.029, 95%CI 1.328–3.098).
This analysis showed that, when properly selected by the heart team and oncologists, most cancer patients undergoing TAVR can achieve a good survival and eventually die of other diseases. Blood malignancies seem to carry a poor prognosis in these patients.
Clinical trial registration:ClinicalTrials.gov Identifier: NCT03385915; https://clinicaltrials.gov/ct2/show/NCT03385915.
•It is controversial whether cancer patients undergoing TAVR have worse prognosis.•This nationwide registry showed that 20% of patients scheduled for TAVR had cancer.•Provided appropriate selection, cancer patients have favorable survival after TAVR.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2020.03.038</identifier><identifier>PMID: 32216975</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aortic Valve - surgery ; Aortic Valve Stenosis - diagnostic imaging ; Aortic Valve Stenosis - surgery ; Cancer ; Humans ; Malignancy ; Neoplasms - surgery ; Registries ; Retrospective Studies ; Risk Factors ; TAVI ; TAVR ; Transcatheter Aortic Valve Replacement ; Treatment Outcome</subject><ispartof>International journal of cardiology, 2020-09, Vol.315, p.86-89</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-dd4f0a90c343bbb72fd78ee827e4c8c1b377737e835a21a949529e0a6632f1393</citedby><cites>FETCH-LOGICAL-c408t-dd4f0a90c343bbb72fd78ee827e4c8c1b377737e835a21a949529e0a6632f1393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167527319355469$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32216975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Biancari, Fausto</creatorcontrib><creatorcontrib>Dahlbacka, Sebastian</creatorcontrib><creatorcontrib>Juvonen, Tatu</creatorcontrib><creatorcontrib>Virtanen, Marko P.O.</creatorcontrib><creatorcontrib>Maaranen, Pasi</creatorcontrib><creatorcontrib>Jaakkola, Jussi</creatorcontrib><creatorcontrib>Laakso, Teemu</creatorcontrib><creatorcontrib>Niemelä, Matti</creatorcontrib><creatorcontrib>Tauriainen, Tuomas</creatorcontrib><creatorcontrib>Vento, Antti</creatorcontrib><creatorcontrib>Husso, Annastiina</creatorcontrib><creatorcontrib>Savontaus, Mikko</creatorcontrib><creatorcontrib>Laine, Mika</creatorcontrib><creatorcontrib>Mäkikallio, Timo</creatorcontrib><creatorcontrib>Raivio, Peter</creatorcontrib><creatorcontrib>Eskola, Markku</creatorcontrib><creatorcontrib>Rosato, Stefano</creatorcontrib><creatorcontrib>Anttila, Vesa</creatorcontrib><creatorcontrib>Airaksinen, Juhani</creatorcontrib><creatorcontrib>Valtola, Antti</creatorcontrib><title>Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer.
This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017.
In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p < 0.0001). Among cancer patients, 18 died of the same disease (at 7 years, mortality 12.5%). Active malignancy was not associated with increased risk of all-cause mortality (adjusted HR 1.100, 95%CI 0.757–1.599). However, patients with blood malignancies had a significantly increased risk of mortality (at 4-year, 53.5% vs. 35.4%, adjusted HR 2.029, 95%CI 1.328–3.098).
This analysis showed that, when properly selected by the heart team and oncologists, most cancer patients undergoing TAVR can achieve a good survival and eventually die of other diseases. Blood malignancies seem to carry a poor prognosis in these patients.
Clinical trial registration:ClinicalTrials.gov Identifier: NCT03385915; https://clinicaltrials.gov/ct2/show/NCT03385915.
•It is controversial whether cancer patients undergoing TAVR have worse prognosis.•This nationwide registry showed that 20% of patients scheduled for TAVR had cancer.•Provided appropriate selection, cancer patients have favorable survival after TAVR.</description><subject>Aortic Valve - surgery</subject><subject>Aortic Valve Stenosis - diagnostic imaging</subject><subject>Aortic Valve Stenosis - surgery</subject><subject>Cancer</subject><subject>Humans</subject><subject>Malignancy</subject><subject>Neoplasms - surgery</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>TAVI</subject><subject>TAVR</subject><subject>Transcatheter Aortic Valve Replacement</subject><subject>Treatment Outcome</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMoun78A5EevXTNVzfpRRBxVRC8qNcwTaeapW3WJF3w35tl1aMw8F6ed4Z5CDlndM4oW1yt5m5lIbRzTjmdU5FH75EZ00qWTFVyn8wypsqKK3FEjmNcUUplXetDciQ4Z4taVTPytoSND9D0WPgpWT_k7AoLo8VQrCE5HFMsprHF8O7d-F6kAGO0kD4wZQJ8SM4WG-g3WARc92BxyJVTctBBH_HsJ0_I6_Lu5fahfHq-f7y9eSqtpDqVbSs7CjW1QoqmaRTvWqURNVcorbasEUopoVCLCjiDWtYVr5HCYiF4x0QtTsjlbu86-M8JYzKDixb7Hkb0UzRcaMkZFXKLyh1qg48xYGfWwQ0QvgyjZmvUrMzOqNkaNVTk0bl28XNhagZs_0q_CjNwvQMw_7lxGEy02ZrF1gW0ybTe_X_hG_lXie4</recordid><startdate>20200915</startdate><enddate>20200915</enddate><creator>Biancari, Fausto</creator><creator>Dahlbacka, Sebastian</creator><creator>Juvonen, Tatu</creator><creator>Virtanen, Marko P.O.</creator><creator>Maaranen, Pasi</creator><creator>Jaakkola, Jussi</creator><creator>Laakso, Teemu</creator><creator>Niemelä, Matti</creator><creator>Tauriainen, Tuomas</creator><creator>Vento, Antti</creator><creator>Husso, Annastiina</creator><creator>Savontaus, Mikko</creator><creator>Laine, Mika</creator><creator>Mäkikallio, Timo</creator><creator>Raivio, Peter</creator><creator>Eskola, Markku</creator><creator>Rosato, Stefano</creator><creator>Anttila, Vesa</creator><creator>Airaksinen, Juhani</creator><creator>Valtola, Antti</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200915</creationdate><title>Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement</title><author>Biancari, Fausto ; Dahlbacka, Sebastian ; Juvonen, Tatu ; Virtanen, Marko P.O. ; Maaranen, Pasi ; Jaakkola, Jussi ; Laakso, Teemu ; Niemelä, Matti ; Tauriainen, Tuomas ; Vento, Antti ; Husso, Annastiina ; Savontaus, Mikko ; Laine, Mika ; Mäkikallio, Timo ; Raivio, Peter ; Eskola, Markku ; Rosato, Stefano ; Anttila, Vesa ; Airaksinen, Juhani ; Valtola, Antti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-dd4f0a90c343bbb72fd78ee827e4c8c1b377737e835a21a949529e0a6632f1393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aortic Valve - surgery</topic><topic>Aortic Valve Stenosis - diagnostic imaging</topic><topic>Aortic Valve Stenosis - surgery</topic><topic>Cancer</topic><topic>Humans</topic><topic>Malignancy</topic><topic>Neoplasms - surgery</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>TAVI</topic><topic>TAVR</topic><topic>Transcatheter Aortic Valve Replacement</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biancari, Fausto</creatorcontrib><creatorcontrib>Dahlbacka, Sebastian</creatorcontrib><creatorcontrib>Juvonen, Tatu</creatorcontrib><creatorcontrib>Virtanen, Marko P.O.</creatorcontrib><creatorcontrib>Maaranen, Pasi</creatorcontrib><creatorcontrib>Jaakkola, Jussi</creatorcontrib><creatorcontrib>Laakso, Teemu</creatorcontrib><creatorcontrib>Niemelä, Matti</creatorcontrib><creatorcontrib>Tauriainen, Tuomas</creatorcontrib><creatorcontrib>Vento, Antti</creatorcontrib><creatorcontrib>Husso, Annastiina</creatorcontrib><creatorcontrib>Savontaus, Mikko</creatorcontrib><creatorcontrib>Laine, Mika</creatorcontrib><creatorcontrib>Mäkikallio, Timo</creatorcontrib><creatorcontrib>Raivio, Peter</creatorcontrib><creatorcontrib>Eskola, Markku</creatorcontrib><creatorcontrib>Rosato, Stefano</creatorcontrib><creatorcontrib>Anttila, Vesa</creatorcontrib><creatorcontrib>Airaksinen, Juhani</creatorcontrib><creatorcontrib>Valtola, Antti</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biancari, Fausto</au><au>Dahlbacka, Sebastian</au><au>Juvonen, Tatu</au><au>Virtanen, Marko P.O.</au><au>Maaranen, Pasi</au><au>Jaakkola, Jussi</au><au>Laakso, Teemu</au><au>Niemelä, Matti</au><au>Tauriainen, Tuomas</au><au>Vento, Antti</au><au>Husso, Annastiina</au><au>Savontaus, Mikko</au><au>Laine, Mika</au><au>Mäkikallio, Timo</au><au>Raivio, Peter</au><au>Eskola, Markku</au><au>Rosato, Stefano</au><au>Anttila, Vesa</au><au>Airaksinen, Juhani</au><au>Valtola, Antti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2020-09-15</date><risdate>2020</risdate><volume>315</volume><spage>86</spage><epage>89</epage><pages>86-89</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><abstract>The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer.
This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017.
In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p < 0.0001). Among cancer patients, 18 died of the same disease (at 7 years, mortality 12.5%). Active malignancy was not associated with increased risk of all-cause mortality (adjusted HR 1.100, 95%CI 0.757–1.599). However, patients with blood malignancies had a significantly increased risk of mortality (at 4-year, 53.5% vs. 35.4%, adjusted HR 2.029, 95%CI 1.328–3.098).
This analysis showed that, when properly selected by the heart team and oncologists, most cancer patients undergoing TAVR can achieve a good survival and eventually die of other diseases. Blood malignancies seem to carry a poor prognosis in these patients.
Clinical trial registration:ClinicalTrials.gov Identifier: NCT03385915; https://clinicaltrials.gov/ct2/show/NCT03385915.
•It is controversial whether cancer patients undergoing TAVR have worse prognosis.•This nationwide registry showed that 20% of patients scheduled for TAVR had cancer.•Provided appropriate selection, cancer patients have favorable survival after TAVR.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32216975</pmid><doi>10.1016/j.ijcard.2020.03.038</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2020-09, Vol.315, p.86-89 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2384210349 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aortic Valve - surgery Aortic Valve Stenosis - diagnostic imaging Aortic Valve Stenosis - surgery Cancer Humans Malignancy Neoplasms - surgery Registries Retrospective Studies Risk Factors TAVI TAVR Transcatheter Aortic Valve Replacement Treatment Outcome |
| title | Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T17%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Favorable%20outcome%20of%20cancer%20patients%20undergoing%20transcatheter%20aortic%20valve%20replacement&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Biancari,%20Fausto&rft.date=2020-09-15&rft.volume=315&rft.spage=86&rft.epage=89&rft.pages=86-89&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2020.03.038&rft_dat=%3Cproquest_cross%3E2384210349%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2384210349&rft_id=info:pmid/32216975&rft_els_id=S0167527319355469&rfr_iscdi=true |